New York – July 31, 2015 – Cooley advised the underwriters on Chiasma, Inc.'s $117.1 million initial public offering. Chiasma is a biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company now trades on The NASDAQ Global Market under the symbol "CHMA."
Barclays Capital Inc. and Cowen and Company, LLC acted as joint book-running managers for the offering. William Blair & Company, LLC and Oppenheimer & Co. Inc. acted as co-managers.
The Cooley corporate securities team was comprised of partners Brent Siler and Div Gupta and associates Mike Kanatake and Pia Kaur.
About Cooley LLP
High-growth and established companies, investors and investment banks focused on technology and life sciences partner with Cooley on transformative deals and high-stakes matters, where innovation meets the law.
Cooley has 850 lawyers across 12 offices in the United States, China and Europe.